Dydrogesterone
Gynorest (dydrogesterone) is a small molecule pharmaceutical. Dydrogesterone was first approved as Gynorest on 1982-01-01. It is used to treat menstruation disturbances in the USA. The pharmaceutical is active against progesterone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dydrogesterone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GYNOREST | Solvay Pharmaceuticals | N-017388 DISCN | 1982-01-01 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| menstruation disturbances | — | D008599 | N91.5 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03D: Progestogen sex hormones and modulators of the genital system
— G03DB: Pregnadien derivatives, progestogens
— G03DB01: Dydrogesterone
— G03F: Progestogens and estrogens in combination
— G03FA: Progestogens and estrogens, fixed combinations
— G03FA14: Dydrogesterone and estrogen
— G03FB: Progestogens and estrogens, sequential preparations
— G03FB08: Dydrogesterone and estrogen
HCPCS
No data
Clinical
Clinical Trials
101 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | — | 2 | 4 | 6 | 11 | 23 |
| Spontaneous abortion | D000022 | EFO_1001255 | O00.1 | — | 1 | 3 | 4 | 2 | 9 |
| Female infertility | D007247 | EFO_0008560 | N97 | — | 1 | 3 | 3 | 2 | 9 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | 1 | 1 | 5 | 7 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 2 | 2 | 1 | 1 | 5 |
| Habitual abortion | D000026 | EFO_1000954 | N96 | — | 1 | 2 | 1 | 1 | 4 |
| Syndrome | D013577 | — | — | — | 1 | 1 | 1 | 1 | 4 |
| Gynatresia | D006175 | EFO_1001335 | N85.6 | 2 | 1 | — | 1 | 1 | 4 |
| Threatened abortion | D000033 | — | O20.0 | — | — | 1 | 2 | 1 | 4 |
| Embryo transfer | D004624 | — | — | — | — | — | 3 | 1 | 4 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 1 | 1 | — | 5 | 7 |
| Postmenopause | D017698 | — | — | — | 1 | 3 | — | — | 3 |
| Pregnancy rate | D018873 | — | — | 1 | — | 1 | — | — | 2 |
| Preimplantation diagnosis | D019836 | — | — | — | — | 1 | — | — | 1 |
| Endometrial hyperplasia | D004714 | — | N85.0 | — | — | 1 | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tissue adhesions | D000267 | — | — | 1 | 1 | — | — | 5 | 6 |
| Ovarian hyperstimulation syndrome | D016471 | — | — | 1 | 1 | — | — | 1 | 3 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian cysts | D010048 | — | N83.1 | 1 | — | — | — | 1 | 2 |
| Cysts | D003560 | — | — | 1 | — | — | — | — | 1 |
| Intracytoplasmic sperm injections | D020554 | — | — | 1 | — | — | — | — | 1 |
| Pregnancy complications | D011248 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 3 | 3 |
| Uterine hemorrhage | D014592 | — | — | — | — | — | — | 2 | 2 |
| Observational studies as topic | D064887 | — | — | — | — | — | — | 2 | 2 |
| Physiological sexual dysfunction | D012735 | — | — | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Metrorrhagia | D008796 | — | N92.1 | — | — | — | — | 1 | 1 |
| Oocyte donation | D018587 | — | — | — | — | — | — | 1 | 1 |
| Hypogonadism | D007006 | — | E23.0 | — | — | — | — | 1 | 1 |
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | — | — | — | — | 1 | 1 |
| Hemophilia b | D002836 | — | D67 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dydrogesterone |
| INN | dydrogesterone |
| Description | Dydrogesterone is a 3-oxo-Delta(4) steroid and a 20-oxo steroid. It has a role as a progestin. |
| Classification | Small molecule |
| Drug class | progestins; steroids (androgens, anabolics); antiandrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |
Identifiers
| PDB | — |
| CAS-ID | 152-62-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200853 |
| ChEBI ID | 31527 |
| PubChem CID | 9051 |
| DrugBank | DB00378 |
| UNII ID | 90I02KLE8K (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,304 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
452 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use